- Home
- XENE vs INDV Comparison
XENE vs INDV Comparison
Compare XENE & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XENE | INDV |
|---|---|---|
| Founded | 1996 | N/A |
| Country | Canada | United States |
| Employees | 370 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.7B |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | XENE | INDV |
|---|---|---|
| Price | $54.29 | $37.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $68.55 | N/A |
| AVG Volume (30 Days) | 803.9K | ★ 2.0M |
| Earning Date | 05-08-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | $311,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2,496.48 | N/A |
| P/E Ratio | ★ N/A | $54.70 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $28.19 | $11.08 |
| 52 Week High | $62.91 | $41.00 |
Technical Indicators
Market Signals| Indicator | XENE | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 43.81 | 58.89 |
| Support Level | $52.92 | $29.71 |
| Resistance Level | $59.43 | $37.83 |
| Average True Range (ATR) | 1.67 | 1.22 |
| MACD | -0.31 | -0.32 |
| Stochastic Oscillator | 23.98 | 37.69 |
Price Performance
Historical ComparisonAbout XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).